BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

Search

Customers Bancorp Inc

Slēgts

SektorsFinanšu

68.01 0.99

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

65.7

Max

69.07

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.3M

74M

Pārdošana

160M

388M

P/E

Sektora vidējais

10.34

54.048

EPS

2.06

Peļņas marža

19.213

Darbinieki

863

EBITDA

29M

131M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+34.69% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 23. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-410M

2.3B

Iepriekšējā atvēršanas cena

67.02

Iepriekšējā slēgšanas cena

68.01

Ziņu noskaņojums

By Acuity

34%

66%

73 / 441 Rangs Finance

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Customers Bancorp Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna
Peļņas
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Customers Bancorp Inc Prognoze

Cenas mērķis

By TipRanks

34.69% augšup

Prognoze 12 mēnešiem

Vidējais 90.78 USD  34.69%

Augstākais 104 USD

Zemākais 71 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Customers Bancorp Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

6

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

50.8248 / 51.75Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

73 / 441 Rangs Finanšu

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Customers Bancorp Inc

Customers Bancorp, Inc. operates as the bank holding company for Customers Bank that provides financial products and services to individual consumers, and small and middle market businesses. The company provides deposit banking products, which includes commercial and consumer checking, non-interest-bearing and interest-bearing demand, MMDA, savings, and time deposit accounts. Its lending business offers commercial and industrial, commercial real estate, and multifamily and residential mortgage loans; SBA lending and financing; specialty lending includes fund finance, real estate specialty finance, technology and venture, and healthcare and financial institutions group; commercial loans to mortgage companies, and commercial equipment financing; and fund finance, such as variable rate loans secured by collateral pools to private debt funds; and cash management services. In addition, the company provides digital banking including Banking-as-a-Service to fintech companies, payments and treasury services to businesses, and consumer loans through fintech companies and the TassatPay, a blockchain-based instant B2B payments platform which offers instant payments including over-the-counter desks, exchanges, liquidity providers, market makers, funds, and other B2B verticals. Further, it offers mobile phone and internet banking, wire transfers, electronic bill payment, lock box, remote deposit capture, courier, merchant processing, cash vault, controlled disbursements, positive pay, and cash management services, such as account reconciliation, collections, and sweep accounts. The company was incorporated in 2010 and is headquartered in West Reading, Pennsylvania.
help-icon Live chat